Deutsche Beteiligungs AG (DBAN)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 18.28 |
|---|---|
| 52-week range | 17.74 – 26.35 |
| Return, 1 month / 3 months | −9.3% / −12.1% |
| Return, 1 year / 3 years | −21.9% / −29.0% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 19.5% |
| Worst drawdown (1 year) | -28.4% |
| Average daily value traded | 0.38M EUR |
| Dividend yield | 5.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Deutsche Beteiligungs AG is a private equity company based in Frankfurt, Germany. It invests in mid-sized businesses, chiefly in German-speaking countries, taking majority or minority stakes and working with management teams to develop those companies. Its portfolio spans industrial and healthcare-related sectors, and it also manages funds on behalf of outside investors. The firm's customers are the companies it backs and the institutions that commit capital to its funds.
The shares are listed on the XETRA Stock Exchange in Germany under the code DBAN, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Deutsche Beteiligungs AG (DBAN) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 18.28 on 23 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 421 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.9% and over the last three months it fell 12.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 24 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.2% | ||
| From 52-week high | -29.8% | ||
| Momentum | 25 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -12.1% | ||
| 6-month return | -24.4% | ||
| 12-month return, skipping the last month | -14.0% | ||
| Stability (higher is calmer) | 75 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 19.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.4% | ||
| Liquidity | 62 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.38M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 68 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.5% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −2.8% |
|---|---|
| 1 month | −9.3% |
| 3 months | −12.1% |
| 6 months | −24.4% |
| 1 year | −21.9% |
| 3 years | −29.0% |
| 5 years | −41.8% |
Signals
| 50-day / 200-day average | 20.05 / 22.62 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jun 2026 | EUR 1.0000 |
| 28 May 2025 | EUR 1.2500 |
| 23 Feb 2024 | EUR 1.0000 |
| 1 Mar 2023 | EUR 0.8000 |
| 18 Feb 2022 | EUR 1.6000 |
| 26 Feb 2021 | EUR 0.8000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.